NCT03426033View on ClinicalTrials.gov

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

February 25, 2018

Study Completion Date

February 25, 2018

Conditions

Elevated Lipoprotein(a)Cardiovascular Diseases

Interventions

DRUG

ISIS 681257

Xmg dose administered as a subcutaneous injection

DRUG

Warfarin

25mg tablet administered orally

Trial Locations (1)

H3P 3H5

Clinical Site, Mount Royal

Sponsors

Lead Sponsor

Akcea Therapeutics

All Listed Sponsors

lead

Akcea Therapeutics

INDUSTRY

NCT03426033 - Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin | Biotech Hunter | Biotech Hunter